"id","rationale","instanceType","uuid:ID","name","label","description"
"StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign","ed6cbdde-e091-48ba-9cfc-9de37d06f033","Study Design 1","","The main design for the study"
